Guideline for management of postmeal glucose in diabetes.

METHODOLOGY Methodology This update builds on the original IDF Guideline for the Management of PostMeal Glucose published in 2007. The methodology used in the development of this guideline is not described in detail here, as it broadly follows the principles described in the IDF Guide for Guidelines (www.idf.org). In summary: • The update was overseen by a Guideline Development Group of clinicians and researchers with expertise in the topic and guideline development (see Members of the Guideline Development Group). • Geographical representation included various IDF regions and countries in different states of economic development. • The evidence used in developing this guideline inclu ded reports from key meta-analyses, evidence-based reviews, clinical trials, cohort studies, epidemiological studies, animal and basic science studies, position statements and guidelines (English language only). Evidence relating to both postmeal and postchallenge plasma glucose was considered and cited as appropriate. Members of the Guideline Development Group were asked to identify any relevant reports or publications. • The evidence was graded according to criteria presented in Table 1. • The Guideline Development Group met at a 2-day workshop held in May 2011 to review the evidence and to update or revise the evidence statements and recommendations. A recommendation was made according to the level of scientific substantiation based on evidence ratings whenever possible. However, when there was a lack of supporting studies, the Guideline Development Group formulated a consensus recommendation. • The final guideline is being made available in paper form and on the IDF website. • IDF will consider the need to review and update this guideline within three to five years. 3 Duality of interest Members of the Guideline Development Group have declared relevant duali-ties of interest in the topic and in relationships with commercial enterprises, govern ments and non-governmental organizations. No fees were paid to the Guideline Development Group members in connection with the current activity. Members of the Guideline Development Group (except for Antonio Ceriello and Stephen Colagiuri) were not aware of the identity of the sponsors during the entire development of this guideline. These companies did not take part in any aspect of the development of this guideline. level Type of Evidence 1++ • High-quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias 1+ • Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias 1-• Meta-analyses, systematic reviews of …